Given the nearly 25% frequency of KRas mutations in non-small-cell lung cancer (NSCLC), we set out to utilize NSCLC as a model system to identify this novel antitumor strategy for targeting the intermediate conformation structure. This evidence concerns the gene KRAS and non-small cell lung carcinoma.